Sign up for myAVOS Beta and unlock better cognitive care

AVOS
  • Home
  • HOW IT WORKS
  • WHO BENEFITS
  • ARTICLES & RESOURCES
  • SHOPPING
  • About us
    • Meet the Team
    • Our Scientific Advisors
  • More
    • Home
    • HOW IT WORKS
    • WHO BENEFITS
    • ARTICLES & RESOURCES
    • SHOPPING
    • About us
      • Meet the Team
      • Our Scientific Advisors
AVOS
  • Home
  • HOW IT WORKS
  • WHO BENEFITS
  • ARTICLES & RESOURCES
  • SHOPPING
  • About us
    • Meet the Team
    • Our Scientific Advisors

FOUNDERS

Dr Le Dam, Co-Founder and CEO of OptiChroniX

Le Dam MD MPH

Le Dam MD MPH

Le Dam MD MPH

CEO 


Le is a medical doctor and experienced startup leader in developing hardware, software, and AI/ML medical device solutions that deliver value to clinicians and patients. She managed a network of clinicians and healthcare leaders committed to developing innovative technologies to improve health outcomes and decrease the burden on clini

CEO 


Le is a medical doctor and experienced startup leader in developing hardware, software, and AI/ML medical device solutions that deliver value to clinicians and patients. She managed a network of clinicians and healthcare leaders committed to developing innovative technologies to improve health outcomes and decrease the burden on clinicians and the healthcare system.


Le previously secured 5.7 million in federal SBIR grant funding and supported several successful regulatory submissions including FDA 510k and Breakthrough Device Designation. 


She conducted and published public health research and guidelines in collaboration with The University of Melbourne for the National Health and Medical Research Council in Australia.


Le received her BA from UCLA, Masters of Public Health from the University of Queensland, and her medical degree from the University of Notre Dame Sydney School of Medicine.

Rene Gilvert, Founder and COO of OptiChroniX

Rene Gilvert

Le Dam MD MPH

Le Dam MD MPH

Chair and COO


René is a life science professional with more than 25 years of pharmaceutical commercial and development experience in GSK, Organon, Novartis and Takeda


Former Vice President of Global Franchises in Neuroscience and CVM at Takeda

René has more than 10  years of leadership experience in developing Digital Solutions , at both No

Chair and COO


René is a life science professional with more than 25 years of pharmaceutical commercial and development experience in GSK, Organon, Novartis and Takeda


Former Vice President of Global Franchises in Neuroscience and CVM at Takeda

René has more than 10  years of leadership experience in developing Digital Solutions , at both Novartis and Takeda, where he developed Digital Medicine concepts in NeuroPsychiatric disorders.

René  holds a B.Sc in Information Management from the University of Applied Sciences Larenstein and has Executive Training certification in Finance from the Harvard Business School

TeaM

Dr Roger Bullock, Chief Medical Officer at OptiChroniX

Roger Bullock MD

Albrecht Tribukait PhD MDA

Albrecht Tribukait PhD MDA

Medical Officer


Roger qualified in medicine 1981 and has worked in surgery, medicine and A&E until training in psychiatry 1987-1990.


Specialized in geriatric psychiatry.
NHS consultant 1993-2013
Set up Kingshill Research Centre in 1994 developing it in to a national and international facility. 


UK coordinating investigator on many occasions

Medical Officer


Roger qualified in medicine 1981 and has worked in surgery, medicine and A&E until training in psychiatry 1987-1990.


Specialized in geriatric psychiatry.
NHS consultant 1993-2013
Set up Kingshill Research Centre in 1994 developing it in to a national and international facility. 


UK coordinating investigator on many occasions. Published over 100 peer reviewed papers, several books and chapters and
8 years as clinical tutor and 4 years as Academic Secretary of the Royal College of Psychiatrists Faculty of Old age Psychiatry. Invited speaker at many national and international conferences

Worked 11 years in senior NHS management - last six as Clinical director of Older Peoples services.

Successfully responsible for a 55m budget and clinical governance of 800 staff

Dr Albrecht Tribukait, Chief Regulatory and Compliance Officer at OptiChroniX

Albrecht Tribukait PhD MDA

Albrecht Tribukait PhD MDA

Albrecht Tribukait PhD MDA

Regs and Compliance Officer


Albrecht is a transformational leader with an international career of more than 20 years at the interface of science, policy and regulation in fast-paced Biotech and FMCG environments of significant growth.


Extensive experience in national and supranational regulation of consumer products and non-food products.


A

Regs and Compliance Officer


Albrecht is a transformational leader with an international career of more than 20 years at the interface of science, policy and regulation in fast-paced Biotech and FMCG environments of significant growth.


Extensive experience in national and supranational regulation of consumer products and non-food products.


Albrecht has conducted, directed, commissioned and published scientific and clinical research, and forged first-in-class partnerships with NGO and strategic collaboration with government-owned research organisations advancing evidence-informed approaches to public health policy and practice. 


Ph.D. in Natural Sciences from the University of Göttingen, MBA from Anaheim University Akio Morita School of Business, postgraduate certificates from Oxford and Hull.

Anna Grabowski, Chief Finance Officer at OptiChroniX

Anna Grabowski MSc

Anna Grabowski MSc

Anna Grabowski MSc

Financial Officer


Anna has significant experience in controlling, strategy & risk management with major global fast moving consumer good companies.


She is the  Head of Basel Section and Board member of the Swiss Hospital Service of the Order of Malta.


Anna holds an M.Sc. (cum laude) International Management/CEMS from Rotterdam School of Mana

Financial Officer


Anna has significant experience in controlling, strategy & risk management with major global fast moving consumer good companies.


She is the  Head of Basel Section and Board member of the Swiss Hospital Service of the Order of Malta.


Anna holds an M.Sc. (cum laude) International Management/CEMS from Rotterdam School of Management and executive education at IMD Lausanne and IESE Business School. 


Anna is an alumna of Evonik’s RISE talent program and a One Young World Ambassador

Mark Edwards, Corporate Secretary at OptiChroniX

Mark Edwards

Anna Grabowski MSc

Anna Grabowski MSc

Corporate Secretary


Mark has 27 years of global legal experience
Former Vice President and  General Counsel of Butamax®Advanced Biofuels LLC (Joint Venture between BP and DuPont)

He was General Counsel and Compliance Officer of Ilera Healthcare, a successful startup 

Corporate Intellectual Property Litigation Counsel for DuPont strategic b

Corporate Secretary


Mark has 27 years of global legal experience
Former Vice President and  General Counsel of Butamax®Advanced Biofuels LLC (Joint Venture between BP and DuPont)

He was General Counsel and Compliance Officer of Ilera Healthcare, a successful startup 

Corporate Intellectual Property Litigation Counsel for DuPont strategic businesses - 13 years

Extensive technology, licensing and commercial transaction experience

Registered U.S. Patent Attorney - United States Patent and Trademark OfficeIntellectual Property consultant for startups and emerging companies

B.A. Chemistry - Kenyon College

Company Logo OptiChroniX

the company behind myAVOS

OptiChroniX is a Swiss-American digital health company that aims to improve brain health for millions. 


We developed myAVOS, a healthcare application that provides a late-life dementia risk calculator,  continuous screening for cognitive change, focusing on modifiable factors in one's lifestyle and health status as early as for people in their mid fifties. 


myAVOS uses digital technology to personalize, track and improve brain health by collecting data from wearables and nearables, and providing tailored coaching to improve health literacy, medication adherence and positively impact modifiable factors related to cognitive decline. Forty per cent of dementia cases could be prevented or delayed by targeting modifiable risk factors.



  • HOW IT WORKS
  • WHO BENEFITS
  • ARTICLES & RESOURCES
  • PRIVACY POLICY
  • EULA
  • Terms and Conditions
  • References

myAVOS

Copyright © 2019 - 2023 

myAVOS, OptiChroniX GmbH and OptiCHRONIX INC

All Rights Reserved.

myAVOS - Patent Pending

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept